An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer.

Trial Profile

An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms ACCELERATE
  • Sponsors Amgen
  • Most Recent Events

    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12606000030572).
    • 20 Nov 2008 Status changed from recruiting to completed, according to clinicaltrials.gov.
    • 20 Nov 2007 New trial centres added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top